S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Germany's Merck Cautious After Deal Spree -- Update (2015/3/3)|
|Merck Profit Slips Despite Revenue Gains (2015/3/3)|
|Merck KGaA 4Q 2014 -- Forecast (2015/2/27)|
|Sigma-Aldrich Stockholders Approve Acquisition By Merck KGaA (2014/12/5)|
|Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance (2014/12/23)|
|Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting (2014/12/6)|
|Sigma-Aldrich (NASDAQ - SIAL) Reports Record Full-Year 2014 Sales Of $2.79 Billion And Record Adjusted Diluted EPS Of $4.37. Reports Q4 2014 Adjusted Diluted EPS Of $1.14 And Organic Sales Growth Of 7%. Declares $0.23 Per Share Quarterly Dividend. (2015/2/12)|
|PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE (2015/1/27)|
|BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome (2014/12/7)|
|BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome (2014/12/10)|
Click above to view more mutual fund data and stats for mkgay - Merck KGaA ADR.